Yesilbursa D, Serdar Z, Serdar A, Sarac M, Coskun S, Jale C
Cardiology Department, Uludag University Medical School, Bursa, Turkey.
Int J Obes (Lond). 2005 Jan;29(1):142-5. doi: 10.1038/sj.ijo.0802794.
Obesity is a well-known risk factor of atherosclerosis. Recent studies showed that obesity is associated with enhanced lipid peroxidation. The aim of this study is to investigate the effect of weight reduction with orlistat treatment on lipid peroxidation levels. We assessed lipid peroxidation by measuring the concentration of plasma malondialdehyde (MDA).
A randomized, controlled, open-label 6-month study.
In total, 36 obese (body mass index (BMI) >30 kg/m2) and 11 healthy age-matched control subjects were enrolled in the study.
Fasting glucose, triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol and MDA levels were measured in both groups. Obese subjects received orlistat, 120 mg three times daily together with hypocaloric diet. After 6 months of treatment laboratory tests were repeated.
MDA levels were significantly higher in obese patients than the control group (P<0.0001). After 6 months of treatment in obese subjects, the mean weight of the patients decreased by 6.8 kg, the BMI by 3.2 kg/m2. Plasma MDA levels were significantly reduced by weight loss from 2+/-0.77 to 0.89+/-0.41 nmol/ml (P<0.001). BMI correlated with MDA levels at baseline (r=0.6, P<0.0001). Changes in BMI was positively associated with plasma MDA level reduction (r=0.36, P<0.05).
These results indicate that obesity is associated with increases in endogenous lipid peroxides. Our data show that the indicator of lipid peroxidation-MDA-falls markedly in association with weight loss with orlistat. The demonstration of decreased free radical generation has important implications for oxidative mechanism underlying obesity-associated disorders.
肥胖是动脉粥样硬化的一个众所周知的危险因素。最近的研究表明，肥胖与脂质过氧化增强有关。本研究的目的是探讨奥利司他治疗减重对脂质过氧化水平的影响。我们通过测量血浆丙二醛（MDA）浓度来评估脂质过氧化。
一项随机、对照、开放标签的6个月研究。
总共36名肥胖者（体重指数（BMI）>30kg/m²）和11名年龄匹配的健康对照者纳入本研究。
两组均测量空腹血糖、甘油三酯、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和MDA水平。肥胖受试者接受奥利司他治疗，每日3次，每次120mg，同时采用低热量饮食。治疗6个月后重复进行实验室检查。
肥胖患者的MDA水平显著高于对照组（P<0.0001）。肥胖受试者治疗6个月后，患者平均体重下降6.8kg，BMI下降3.2kg/m²。体重减轻使血浆MDA水平从2±0.77显著降至0.89±0.41nmol/ml（P<0.001）。BMI与基线时的MDA水平相关（r=0.6，P<0.0001）。BMI的变化与血浆MDA水平降低呈正相关（r=0.36，P<0.05）。
这些结果表明，肥胖与内源性脂质过氧化物增加有关。我们的数据显示，脂质过氧化指标MDA与奥利司他减重显著下降有关。自由基生成减少的证明对肥胖相关疾病的氧化机制具有重要意义。
